Sublingual immunotherapy for treating allergic conjunctivitis

Calderón, Moisés A.; Penagos, Martín; Sheikh, Aziz; Canonica, Giorgio Walter; Durham, Stephen R.

doi:10.1002/14651858.cd007685

Cited by 15 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, more recent metaanalyses, restricted to house dust mite and grasses [19,20] confirmed the results with a lesser hetero geneity grade. Finally, the superiority of SLIT over pla cebo was confirmed, also limiting the ana lysis to conjunctivitis symptoms [21].…”

Section: Slit For Allergic Rhinoconjunctivitismentioning

confidence: 78%

“…In the 60 positive studies, the degree of clinical effect ranged from 10 to 45% over placebo with greater than 20% in about twothirds. When analyzing the available trials, it was noted that some meta analyses were continued, sub dividing patients for age, allergen or disease (Table 1) [14][15][16][17][18][19][20][21]. Four metaanalyses evaluated the use of SLIT con sidering only allergic rhinitis for symptoms and drug intake [14,17,19,20] (three included patients of all ages [14,19,20] and the fourth only patients aged 5-18 years [17]), all providing results con sistently in favor of SLIT versus placebo [22].…”

Section: Slit For Allergic Rhinoconjunctivitismentioning

confidence: 99%

See 1 more Smart Citation

Sublingual Immunotherapy for Allergic Rhinitis and Conjunctivitis

et al. 2013

View full text Add to dashboard Cite

Sublingual immunotherapy (SLIT) for allergic respiratory diseases was first described in 1986 and immediately appeared as a viable alternative to the traditional subcutaneous route. Since then, more than 60 randomized controlled trials have been published, almost all with very favorable results. The average improvement over placebo in symptom score and medication use was always greater than 20%. The results of the clinical trials were pooled in several meta-analyses, which consistently confirmed the efficacy of the treatment. SLIT is characterized by a satisfactory safety profile, its side effects being mainly limited to oral discomfort. Only six anaphylaxes and no fatalities have been so far reported. Due to the good risk:benefit ratio, SLIT is currently being investigated in diseases other than respiratory allergy, such as food allergy and atopic dermatitis.

show abstract

Section: Slit For Allergic Rhinoconjunctivitismentioning

confidence: 78%

Section: Slit For Allergic Rhinoconjunctivitismentioning

confidence: 99%

Sublingual Immunotherapy for Allergic Rhinitis and Conjunctivitis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…More recently, sublingual tablets for house dust mite (HDM) allergy also demonstrated clinical efficacy [21]. Randomized controlled trials (RCT) of SCIT and SLIT showed clinical efficacy, further confirmed by meta-analyses [13,[22][23][24][25] and systematic reviews [26][27][28][29]. SCIT is effective in preventing systemic and large local allergic reactions to insect stings [27] with some data indicating similar success with the sublingual route [30,31].…”

mentioning

confidence: 93%

Current developments for improving efficacy of allergy vaccines

Sandrini

Rolland

O’Hehir

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

Allergic diseases are prevalent worldwide. Allergen immunotherapy (AIT) is a current treatment for allergy, leading to modification of the natural course of disease. Mechanisms of efficacy include Treg through release of IL-10 and TGF-β and specific IgG4 blocking antibodies. Subcutaneous and sublingual routes are popular, but uptake is limited by inconvenience and safety concerns. Inclusion criteria limit application to a small proportion of allergic patients. New forms of immunotherapy are being investigated for more efficacious, convenient and safer options with promising advances in recent years. The rationale of reducing vaccine allergenicity to increase safety while improving immunogenicity led to investigation of T-cell epitope-based peptides and recombinant allergen derivatives. Additionally, different routes of administration and adjuvants and adjunct therapies are being explored. This review discusses the current status of AIT and recent advances to improve clinical efficacy, safety and long-term immune tolerance.

show abstract

“…Anti-symptomatic therapies have markedly improved the quality of life of patients, but still do not provide therapeutic benefits for some symptoms and, most importantly, cannot alter the course of the disease. Alternatively, allergen immunotherapy (AI) pretends to induce a long-lasting immune tolerance to allergens by modifying the natural course of the allergic disease [161,162]. Focused on this aim, AI targets in Th2 cells pathophysiologically triggered various tolerogenic mechanisms (T cell anergy or deletion, Treg-mediated suppression of T-effector responses, or Th skewing to Th1) by specific allergens (see recent review [163]).…”

Section: Lps As Immunomodulator In Immune Disordersmentioning

confidence: 99%

The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development

Arenas

2012

EMIDDT

View full text Add to dashboard Cite

Bacterial lipopolysaccharide (LPS, endotoxin) is the major constituent of the outer membrane of Gram-negative bacteria. LPS can cause a variety of immune- and cellular disorders that lead to lethal effects and clinical manifestations of infectious diseases. Several molecular and cellular in vitro techniques, besides synthesis of analogous molecules of the LPS active region, have provided insight in the molecular mechanisms of LPS bioactivity in cellular systems. These advances have facilitated the application of diverse LPS-based molecules in relevant areas such as vaccine technology, allergen immunotherapy, treatment of immune-related diseases/disorders, LPS-related inflammatory processes and sepsis. The purpose of this review is to examine the progress in the generation of new LPS-based molecules and their therapeutic potential.

show abstract

Sublingual immunotherapy for treating allergic conjunctivitis

Cited by 15 publications

References 23 publications

Sublingual Immunotherapy for Allergic Rhinitis and Conjunctivitis

Sublingual Immunotherapy for Allergic Rhinitis and Conjunctivitis

Current developments for improving efficacy of allergy vaccines

The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development

Contact Info

Product

Resources

About